AzTrials
AzTrials

Myocardial InfarctionNCT04460482

Near-infrared Spectroscopy Guided Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction

A study testing Near-infrared spectroscopy (NIRS) and Angiography in people with Myocardial Infarction and Coronary Artery Disease, run by Odense University Hospital at 1 site in Denmark.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The aim of this study is to investigate whether near-infrared guided percutaneous coronary intervention in patients with acute myocardial infarction provides improved stent strut coverage at six months compared to conventionally angiography guided percutaneous coronary intervention. Read more about this study

Who is it for?
Ages 18 to 80 years
What is being tested?
Near-infrared spectroscopy (NIRS) and Angiography
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
104 participants
Where
1 siteDenmark
Study dates
1 Sep 2020to 2 Mar 2023
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 80 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patients with acute coronary syndrome (ST-elevation myocardial infarction and non-ST elevation myocardial infarction) referred for invasive coronary angiography and percutaneous coronary intervention at Department of Cardiology, Odense University Hospital (Odense, Denmark)

Who cannot join

  • participation in other randomized clinical trials
  • life expectancy < 1 year
  • allergy to aspirin, clopidogrel, ticagrelor or prasugrel
  • eGFR < 30 mL/min
  • tortuous and angiographically estimated extremely calcified lesions
  • ostial, left main and bifurcation lesions
Show all 9Show fewer
  • lesions in a reference vessel diameter < 2.0 mm
  • hemodynamic instability
  • Scheduled for coronary artery bypass grafting

Trial locations and contacts

1 site in 1 country.

Denmark1 site
  • Manijeh Noori

    Odense, 5000

Other trials in Denmark

About this study

The aim of this study is to investigate whether near-infrared guided percutaneous coronary intervention in patients with acute myocardial infarction provides improved stent strut coverage at six months compared to conventionally angiography guided percutaneous coronary intervention.

Read the detailed description

Background Myocardial infarction (MI) secondary to atherosclerotic coronary artery disease is mainly due to plaque-rupture with formation of a luminal thrombogenic material. Lesions responsible for MI are more frequently composed of lipid-rich plaques (LRP) in both culprit and in non-culprit lesions compared to lesions in patients with stable angina.

LRP is thought to be main precursor for future coronary events and may also have an impact on complications following percutaneous coronary intervention (PCI). It has been previously indicated that stent thrombosis (ST) and restenosis often occur when stenting a lipid-rich plaque. And if using angiography guidance only during PCI, there is a potential risk of implantation of a stent edge on a lipid pool, which can result in incomplete stent coverage of a lesion. The incidence of restenosis and ST may be related to the lesion characteristics, clinical presentation, antithrombotic treatment and stent design. Other factors may include inflammatory reaction to the polymer coating containing drug that delays vascular healing, insufficient stent strut coverage and incomplete stent apposition (ISA).

Invasive imaging modality can contribute to better understanding of the changes that occur in the vessel wall during stent implantation.

Intravascular ultrasound (IVUS) combined with a new imaging modality called near-infrared spectroscopy (NIRS) can identify LRP and provide a semi-quantitative estimate of amount of LRP present within selected region of interest. The method is excellent to identify ISA and improve stent implantation technique.

Optical coherence tomography (OCT) is a high resolution imaging modality that can analyze healing pattern after stent implantation such as stent strut coverage.

Method The study is designed as a prospective randomized trial conducted at a single center (Odense University Hospital). Patients with MI will be enrolled if they fulfill the criteria. The study is submitted and approved by The Regional Committees on Health Research Ethics for Southern Denmark (Project-ID: S-20200010) and Danish Data Agency (Journal nr.: 20/18008).

Eligible patients will be randomly assigned to either NIRS-guided PCI or conventual angiography-guided PCI with implantation of Everolimus-eluting Xience stent, which is CE marked. NIRS will be performed in both groups after predilation and stent implantation. In NIRS-guided group the analyses will be used to identify LRP, and to measure vessel wall diameter in reference segments and lesion length. In angiography-guided group the analyses will not be available for the PCI operator and are for observation purpose only. OCT will be performed in both groups after stent implantation, but will be only available for interpretation in NIRS-guided group. In case of reintervention in NIRS-guided group, a final OCT will be performed.

Optimal PCI criteria were following: 1) minimum stent area (MSA) ≥ 5.5 mm2 and ≥ 90% of the distal reference lumen area; 2) no major stent malapposition; 3) plaque burden < 50% at stent edge border; 4) LCBI4mm < 150 in reference segments; and 5) no major stent edge dissection. In case of 1-3, we recommended additional post-dilatation, and in case of 4-5 we recommended an additional stent.

A significant LRP was with lipid-core burden index (maxLCBI4mm) ≥ 150.

Patients will be contacted by telephone to evaluate the clinical situation and to reduce the potential risk of dropout. After 6 months OCT will be performed in both groups to evaluate stent strut coverage and vessel healing.

Statistics Assuming data are normally distributed, categorical data will be presented as numbers and frequencies and compared using chi2-test. Continuous data will be presented as mean ± SD and compared using Student t test. SPSS version 26.0 will be used for the statistical analysis.

Sample size calculation Based on a previous study IVUS-guided PCI in STEMI, the percentage of covered stent struts was 85.4%±7.9. We hypothesized that the coverage in angiography-guided group will be lower by 5.6% at 6 month. A sample size of 86 patients (43 patients in each group) was required for the study to have a power of 80% and two-tailed significance level of 0.05. We expected a dropout rate of 20%, and 104 patients were required to be recruited in the trial.

Sato N, Minami Y, Shimohama T, Kameda R, Tojo T, Ako J. Vascular response and intrastent thrombus in the early phase after drug-eluting versus bare-metal stent implantation in patients with ST-segment elevation myocardial infarction: An observational, single-center study. Health Sci Rep. 2019;2(1):e105.

Being tested
Near-infrared spectroscopy (NIRS), Angiography
Keywords
drug-eluting stent, near-infrared spectrocopy, intravascular ultrasound, optical coherence tomography
Medical subject headings
Myocardial Infarction, Coronary Artery Disease, Myocardial Ischemia, Atherosclerosis, Vascular Diseases

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Near-infrared spectroscopy (NIRS)Device

    NIRS-guided PCI

  • AngiographyDevice

    Angiography guided PCI

Study groups in NCT04460482
Study groupRoleWhat they receive
NIRS-guided PCIActive comparatorNear-infrared Spectroscopy guided Percutaneous coronary intervention with implantation of drug-eluting stent
Receives: Device: Near-infrared spectroscopy (NIRS)
Angiography-guided PCIActive comparatorAngiography-guided percutaneous coronary intervention with implantation of a drug-eluting stent
Receives: Device: Angiography

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Proportion of stent strut coverage

    Proportion of stent strut coverage at 6 months follow up estimated by OCT

    Measured: 6 months after index percutaneous coronary intervention

Secondary outcomes (3)
  1. Uncovered stent struts

    Measured: 6 months after index percutaneous coronary intervention

  2. Persistent stent malapposition

    Measured: 6 months after index percutaneous coronary intervention

  3. Maximal neointimal growth

    Measured: 6 months after index percutaneous coronary intervention

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted7 Jul 2020
  2. Study start1 Sep 2020
  3. Primary completion1 Sep 2022
  4. Study completion2 Mar 2023

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
Eligible patients randomized to NIRS-guided or standard angiographic-guided intervention with DES
Masking
Double blind
Who is masked
Investigator, Outcomes assessor
Enrolment
104 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04460482
Sponsor's protocol ID
s-20200010
Status last verified
Jun 2025
First submitted
2 Jul 2020
Last updated
11 Jun 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Noori M, Hougaard M, Maehara A, Troan J, Hansen KN, Junker A, Hansen HS, Veien K, Ellert J, Lassen JF, Jensen LO. Multimodality Intravascular Imaging Guidance (NIRS-IVUS-OCT) Compared to Angiography-Guided Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction: The NIRVUS Trial. Catheter Cardiovasc Interv. 2026 Jul 28. doi: 10.1002/ccd.70765. Online ahead of print.

    PubMed 42521403

Questions about this trial

What is this clinical trial studying?

A study testing Near-infrared spectroscopy (NIRS) and Angiography in people with Myocardial Infarction and Coronary Artery Disease, run by Odense University Hospital at 1 site in Denmark.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 11 Jun 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Proportion of stent strut coverage (time frame: 6 months after index percutaneous coronary intervention). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04460482, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Jun 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in